Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis

American Journal of Cardiology

Volumn 82, Issue 2, 1998, Pages 144-147

  Sekiya, Michihito ^a   Funada, Junichi ^b   Watanabe, Kouki ^b   Miyagawa, Masao ^b   Akutsu, Hiroshi ^b  

^a National Hospital Organization Ehime Medical Center   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; PROBUCOL;

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROBUCOL; PROSPECTIVE STUDIES; RECURRENCE; STENTS; TETRAZOLES; TREATMENT OUTCOME;

EID: 0032527933     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00323-3     Document Type: Article

References (8)

1. 1. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132:23-29.
2. 2. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Tkai H, Tmai T, Nakai T, Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cell in Culture. J Cardiovasc Pharmacol 1992;20:900-906.
3. 3. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, Guise P, for the multivitamines and probucol study group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-372.
4. 4. Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardiovasc Drug Rev 1993; 11:451-465.
5. 5. Ikeda Y, Kikuchi M, Murakami H. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo: randomized, double-blind cross-over study. Arzneimittelforschung 1987;37:563-566.
6. 6. Mishima Y, Tanaba T, Sakaguchi S, Katsumura T, Kusaba A, Uchida H. Clinical evaluation of OPC-13013 on chronic arterial occlusive disease-a double-blind study with ticlopidine. Igaku no Ayumi 1986;139:133-157.
7. 7. Ochiai M, Isshiki T, Takeshita S, Eto K, Toyoizumi H, Sato T, Miyashita H. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. Am J Cardiol 1997;79:1471-1474.
8. 8. Take S, Matsutani M, Ueda H, Hamagushi H, Konishi H, Baba Y, Kawaratani H, Sugiura T, Iwasaka T, Inada M. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1997;79:1097-1099.